Nintedanib (Vargatef®) Plus Docetaxel in Second Line of Treatment in Patients With Lung Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

59

Participants

Timeline

Start Date

September 30, 2015

Primary Completion Date

September 26, 2020

Study Completion Date

September 26, 2020

Conditions
Lung Neoplasms
Interventions
DRUG

vargatef®

Patients will be treated to oral nintedanib (vargatef®) 400 mg/d on days 2 to 21 of a 3-week cycle

DRUG

Docetaxel

Patients will be treated to IV docetaxel 75 mg/m² on day 1 of evry 3-week cycle

Trial Locations (11)

78200

Centre Hospitalier F. Quesnay, Mantes-la-Jolie

87000

CHU de Limoges, Limoges

Unknown

CH de Beauvais, Beauvais

CHU Brest, Brest

Service de Pneumologie, Créteil

Service de Pneumologie, Gap

CH de Bretagne Sud, Lorient

AP-HM, Marseille

Institut Paoli-Calmettes, Marseille

Instiut de Cancérologie, Saint-Etienne

Service de Pneumologie, Villefranche

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Boehringer Ingelheim

INDUSTRY

lead

University Hospital, Limoges

OTHER